Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 15/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688004 | 0.95 | PTGER3 (0.44) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL687238 | 0.94 | PTGER3 (0.46) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL688040 | 0.94 | PTGER3 (0.49) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL688155 | 0.94 | PTGER3 (0.49) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL687152 | 0.93 | PTGER3 (0.48) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL27587444 | 0.92 | KDM4E (0.42) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL688366 | 0.92 | PTGER3 (0.46) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL687672 | 0.92 | CYP26A1 (0.43) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL687043 | 0.91 | CTSA (0.45) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL686873 | 0.91 | PTGER3 (0.49) | PTGER3KDM4EALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176956-B1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| JP-2002544161-A | — | — | 2002-12-24 | — | — | JP | claimed |
| WO-2000067746-A9 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-29 | — | — | WO | claimed |
| EP-1176956-A4 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-28 | — | — | EP | claimed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1176956-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000067746-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-16 | — | — | WO | claimed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1176956-B1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2000067746-A9 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | PTGER3 2942/4885KDM4E 2631/4885ALDH1A1 53/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | PTGER3 2649/4885KDM4E 3292/4885ALDH1A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.